Evolving role of novel agents for maintenance therapy in myeloma

Cancer Journal

Volumn 15, Issue 6, 2009, Pages 494-501

  Magarotto, Valeria ^a   Palumbo, Antonio ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

Bortezomib; Consolidation; Lenalidomide; Maintenance; Multiple myeloma; Thalidomide

Indexed keywords

ALPHA INTERFERON; ALPHA2B INTERFERON; ANTINEOPLASTIC AGENT; BORTEZOMIB; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; LENALIDOMIDE; MELPHALAN; PAMIDRONIC ACID; PLACEBO; PREDNISOLONE; PREDNISONE; STEROID; THALIDOMIDE; VINCRISTINE;

ANEMIA; AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; CONSTIPATION; CONTINUOUS INFUSION; DEEP VEIN THROMBOSIS; DISEASE COURSE; DIZZINESS; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; DYSPNEA; EVENT FREE SURVIVAL; FATIGUE; FEBRILE NEUTROPENIA; FOLLOW UP; GASTROINTESTINAL TOXICITY; HERPES VIRUS INFECTION; HERPES ZOSTER; HUMAN; INFECTION; INTESTINE OBSTRUCTION; MAINTENANCE THERAPY; MAXIMUM TOLERATED DOSE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MUSCULOSKELETAL DISEASE; NEUROPATHY; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RASH; RECOMMENDED DRUG DOSE; REVIEW; SYNCOPE; THROMBOCYTOPENIA; THROMBOEMBOLISM; THROMBOSIS; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT RESPONSE; VASCULITIS;

ADRENAL CORTEX HORMONES; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC AGENTS, HORMONAL; BORONIC ACIDS; DEXAMETHASONE; DRUG THERAPY, COMBINATION; HUMANS; MELPHALAN; MULTIPLE MYELOMA; PREDNISOLONE; PROTEASE INHIBITORS; PYRAZINES; THALIDOMIDE;

EID: 75149135755     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/PPO.0b013e3181c51f24     Document Type: Review

References (32)

1. Berenson JR, Crowley JJ, Grogan TM, et al. Maintenance therapy with alternate day prednisone improves survival in multiple myeloma patients. Blood. 2002;99:3163-3168.
2. Shustik C, Belch A, Robinson S, et al. A randomised comparison of melphalan with prednisone or dexamethasone as induction therapy and dexamethasone or observation as maintenance therapy in multiple myeloma. Br J Hematol. 2006;136:203-211.
3. Cunnigham D, Powles R, Malpas JS, et al. A randomized trial of maintenance therapy with intron A following high dose melphalan and ABMT in myeloma. Br J Haematol. 1998;102:195-202.
4. Barlogie B, Kyle RA, Anderson KC, et al. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US intergroup trial S9321. J Clin Oncol. 2006;24:929-936.
5. Attal M, Harousseau JL, Leyvraz S, et al. Maintenance therapy with thalidomide improves survival in multiple myeloma patients. Blood. 2006;15: 3289-3294.
6. Barlogie B, Pineda-Roman M, van Rhee F, et al. Thalidomide arm of Total Therapy II improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities. Blood. 2008;112:3115-3121.
7. Feyler S, Rawstron A, Jackson G, et al. Thalidomide maintenance following high-dose therapy in multiple myeloma: a UK myeloma forum phase II. Br J Hematol. 2007;139:429-433.
8. Morgan GJ, Jackson GH, Davies FE, et al. Maintenance thalidomide may improve progression free but not overall survival; results form the myeloma IX maintenance randomisation. Blood. 2008;112:656.
9. Spencer A, Prince HM, Roberts AW, et al. Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure. J Clin Oncol. 2009;27:1788-1793.
10. Hussein MA, Bolejack V, Zonder JA. Phase II study of thalidomide plus dexamethasone induction followed by tandem melphalan-based autotransplantation and thalidomide-plus-prednisone maintenance for untreated multiple myeloma: a Southwest Oncology group trial (S0204). J Clin Oncol. 2009;27:1-8.
11. Offidani M, Corvatta L, Polloni C, et al. Thalidomide-dexamethasone versus Interferon-alphadexamethasone as maintenance treatment after ThaDD induction for multiple myeloma: a prospective, multicentre, randomised study. Br J Hematol. 2008;144:653-659.
12. Palumbo A, Bringhen S, Liberati AM, et al. Oral melphalan, prednisone and thalidomide in elderly patients with multiple myeloma: updated results of a randomized control trial. Blood. 2008;112:3107-3114.
13. Wijermans P, Schaafsma P, van Norden P, et al. Melphalan + prednisone versus melphalan + prednisone + thalidomide in induction therapy for multiple myeloma in elderly patients: final analysis of the dutch cooperative group HOVON 49 study. Blood. 2008;112:649.
14. Facon T, Mary JY, Hulin C, et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM99-06) a randozmized trial. Lancet. 2007;370:1209-1218.
15. Hulin C, Facon T, Rodon P, et al. Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial. J Clin Oncol. 2009;27:3664-3670.
16. Ludwig H, Hajek R, Tothova E, et al. Thalidomide-dexamethasone compared with melphalan-prednisone in elderly patients with multiple myeloma. Blood. 2009;113:3435-3442.
17. Drayson MT, Chapman CE, Dunn JA, et al. MRC trial of alpha-2b-interferon maintenance therapy in first plateau phase of multiple myeloma. MRC working party on leukemia in adults. Br J Hematol. 1998;101:195-202.
18. Palumbo A, Falco P, Corradini P, et al. Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA Italian Multiple Myeloma Network. J Clin Oncol. 2007;25:4459-4465.
19. Palumbo A, Falco P, Gay F, et al. Bortezomib-doxorubicin-dexamethasone as induction prior to reduced intensity autologous transplantation followed by lenalidomide as consolidation/maintenance in elderly untreated myeloma patients. Blood. 2008;112:159.
20. Maintenance therapy using lenalidomide in myeloma (IFM 2005-02). NCT00430365. Available at http://clinicaltrial.gov. Accessed January 31, 2007.
21. Weber D, Chen C, Niesvizky R, et al. Lenalidomide plus Dexamethasone for relapsed multiple myeloma in North America. N Engl J Med. 2007;357:2133-2142.
22. Dimopoulos M, Spencer A, Attal M, et al. Lenalidomide plus dexamethasone for relapsed ore refractory multiple myeloma. N Engl J Med. 2007;357:2123-2132.
23. San Miguel JF, Dimopoulos MA, Stadtmauer EA, et al. Longer duration of treatment and maintenance of best response with lenalidomide and dexamethasone prolongs overall survival in patients with relapsed or refractory multiple myeloma. Blood. 2008;112:3702.
24. Richardson PG, Sonneveld P, Schuster M, et al. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood. 2007;110:3557-3560.
25. Palumbo A, Falco P, Sanpaolo G, et al. Combination of lenalidomide, melphalan, prednisone and thalidomide (RMPT) in relapsed/refractory multiple myeloma: results of a Multicenter Phase II clinical trial. Blood. 2008; 112:868.
26. Schiller GJ, Liao M, Sohn JP, et al. Phase I/II trial of bortezomib maintenance in order to prolong remission duration following autologous peripheral blood progenitor cell transplantation as treatment for intermediate and advancedstage multiple myeloma. Blood. 2007;110:3617.
27. Uy GL, Goyal SD, Fisher NM, et al. Bortezomib administered pre-auto-SCT and as maintenance therapy post-transplant for multiple myeloma: a single institution phase II study. Bone Marrow Transpl. 2009;43:793-800.
28. Sonneveld P, van der Holt B, Schimdt-Wolf GH, et al. First analysis of HOVON-65/GMMG-HD4 randomized phase III trial comparing bortezomib, adriamycine, dexamethasone (PAD) vs VAD as induction treatment prior to high dose melphalan (HDM) in patients with newly diagnosed multiple myeloma (MM). Blood. 2008;112:653.
29. Dispenzieri A, Jacobus S, Vesole D, et al. Primari therapy with bortezomibthe role of induction, maintenance and re-induction in patients with high-risk myeloma. Update of results from E2A02. Blood. 2008;112:1738.
30. Palumbo A, Bringhen S, Rossi D, et al. A prospective, randomized, phase iii study of bortezomib, melphalan, prednisone and thalidomide (VMPT) versus bortezomib, melphalan and prednisone (VMP) in elderly newly diagnosed myeloma patients. Blood. 2008;112:652.
31. Benevolo G, LaroccaA, Pregno P, et al. Bortezomib and dexamethasone as maintenance therapy in relapsed/refractory multiple myeloma patients. Blood. 2008;112:abstract 2771.
32. Anderson KC, Jagannath S, Jakubowiak A, et al. Lenalidomide, bortezomib and dexamethasone in relapsed/refractory multiple myeloma (MM): encouraging outcomes and tolerability in phase II study. J Clin Oncol. 2009;27:15s (abstract 8536).